The fact that CKD patients often exhibit dyslipidemia and have high serum levels of free fatty acids28 may contribute to the high serum FGF21 levels, because free fatty acids are endogenous ligands for PPARα29. This evidence concerns the gene FGF21 and metabolic syndrome.